Major objectives To evaluate the efficacy of lparomlimab and Tuvonralimab injection (QL1706, an Anti-PD-1/ CTLA-4 Combined Antibody) in combination with TACE and lenvatinib as second-line therapy in patients with unresectable intermediate-to-advanced hepatocellular carcinoma.
Comprehension and voluntary signing of the study's informed consent form;
Age ≥18 years, any gender;
Histologically or clinically confirmed hepatocellular carcinoma;
Documented failure or intolerance to first-line therapy with PD-1/PD-L1 inhibitor plus bevacizumab;
Inability to comply with the study protocol or procedures;
Histologically/cytologically confirmed fibrolamellar HCC, sarcomatoid HCC, cholangiocarcinoma, or mixed hepatocellular-cholangiocarcinoma;
History of liver transplantation or planned transplantation;
Presence of central nervous system metastases and/or leptomeningeal carcinomatosis;